MCID: BRD004
MIFTS: 50

Borderline Personality Disorder

Categories: Mental diseases

Aliases & Classifications for Borderline Personality Disorder

MalaCards integrated aliases for Borderline Personality Disorder:

Name: Borderline Personality Disorder 12 77 56 45 15 74

Classifications:



External Ids:

Disease Ontology 12 DOID:10930
ICD9CM 36 301.83
MeSH 45 D001883
NCIt 51 C92633
SNOMED-CT 69 20010003
ICD10 34 F60.3
UMLS 74 C0006012

Summaries for Borderline Personality Disorder

Disease Ontology : 12 A personality disorder that involves a prolonged disturbance of personality function characterized by depth and variability of moods.

MalaCards based summary : Borderline Personality Disorder is related to alexithymia and bipolar disorder. An important gene associated with Borderline Personality Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Peptide ligand-binding receptors and cAMP signaling pathway. The drugs Citalopram and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and amygdala, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 77 Borderline personality disorder (BPD), also known as emotionally unstable personality disorder (EUPD),... more...

Related Diseases for Borderline Personality Disorder

Diseases related to Borderline Personality Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 135)
# Related Disease Score Top Affiliating Genes
1 alexithymia 30.7 COMT HTR1A SLC6A4
2 bipolar disorder 30.5 BDNF COMT HTR1A HTR2A SLC6A4 TPH1
3 eating disorder 30.4 BDNF COMT HTR2C SLC6A4
4 antisocial personality disorder 30.3 COMT HTR1B MAOA SLC6A4
5 dysthymic disorder 30.3 HTR2A MAOA SLC6A4
6 bulimia nervosa 30.3 BDNF COMT HTR1B HTR2A SLC6A4
7 substance dependence 30.2 BDNF HTR1B MAOA SLC6A4
8 conduct disorder 30.2 COMT MAOA SLC6A4 TPH1
9 schizophreniform disorder 30.2 COMT PRL
10 atypical depressive disorder 30.2 HTR2A MAOA SLC6A4
11 pain - chronic 30.1 COMT NR3C1
12 anorexia nervosa 30.1 BDNF COMT HTR2A PRL SLC6A4
13 alcohol abuse 30.1 BDNF HTR2A PRL SLC6A4
14 traumatic brain injury 30.1 BDNF COMT
15 avoidant personality disorder 30.0 MAOA SLC6A4 TPH1
16 oppositional defiant disorder 30.0 COMT MAOA SLC6A4
17 intermittent explosive disorder 30.0 HTR1A PRL SLC6A4
18 personality disorder 29.9 AVPR1A BDNF COMT HTR1A HTR1B HTR2A
19 substance abuse 29.9 BDNF COMT HTR1B MAOA PRL SLC6A4
20 schizoaffective disorder 29.9 BDNF COMT HTR2A PRL SLC6A4
21 amnestic disorder 29.8 BDNF HTR1A
22 social phobia 29.8 HTR1A MAOA PRL SLC6A4
23 fibromyalgia 29.8 COMT HTR2A PRL SLC6A4
24 disease of mental health 29.7 BDNF COMT HTR1A HTR2A HTR2C MAOA
25 panic disorder 29.6 COMT HTR1A HTR2A MAOA SLC6A4
26 depression 29.5 BDNF HTR1A HTR2A HTR2C MAOA NR3C1
27 attention deficit-hyperactivity disorder 29.1 BDNF COMT HTR1A HTR1B HTR2A HTR2C
28 bipolar i disorder 29.1 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
29 post-traumatic stress disorder 29.0 BDNF COMT FKBP5 HTR2A MAOA NR3C1
30 generalized anxiety disorder 28.9 BDNF COMT HTR1A HTR2A MAOA SLC6A4
31 schizophrenia 28.8 BDNF COMT HTR1A HTR1B HTR2A HTR2C
32 chronic fatigue syndrome 28.7 COMT HTR1A HTR2A MAOA NR3C1 SLC6A4
33 anxiety 28.6 BDNF COMT HTR1A HTR2A HTR2C MAOA
34 psychotic disorder 28.6 BDNF COMT HTR1A HTR2A HTR2C PRL
35 endogenous depression 28.4 BDNF HTR1A HTR2A MAOA NR3C1 SLC6A4
36 obsessive-compulsive disorder 28.2 BDNF COMT HTR1A HTR1B HTR2A HTR2C
37 mood disorder 28.1 BDNF COMT HTR1A HTR1B HTR2A HTR2C
38 mental depression 28.1 BDNF COMT FKBP5 HTR1A HTR2A HTR2C
39 alcohol dependence 27.9 BDNF COMT HTR1A HTR1B HTR2A HTR2C
40 major depressive disorder 27.6 BDNF COMT FKBP5 HTR1A HTR1B HTR2A
41 multiple personality disorder 11.4
42 impulse control disorder 11.1
43 pol iii-related leukodystrophies 10.6
44 bronchopulmonary dysplasia 10.6
45 cognitive function 1, social 10.4
46 mammographic density 10.3 COMT PRL
47 phobia, specific 10.3 COMT MAOA
48 alcoholic psychosis 10.2 HTR2A SLC6A4
49 early-onset schizophrenia 10.2 BDNF HTR2A
50 tardive dyskinesia 10.2 COMT HTR2A

Comorbidity relations with Borderline Personality Disorder via Phenotypic Disease Network (PDN):


Acute Cystitis Anxiety
Cerebral Atherosclerosis Dependent Personality Disorder
Dysthymic Disorder Hypertension, Essential
Hypothyroidism Major Depressive Disorder
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Borderline Personality Disorder:



Diseases related to Borderline Personality Disorder

Symptoms & Phenotypes for Borderline Personality Disorder

MGI Mouse Phenotypes related to Borderline Personality Disorder:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.22 AVPR1A BDNF COMT FKBP5 HTR1A HTR1B
2 homeostasis/metabolism MP:0005376 10 AVPR1A BDNF COMT FKBP5 HTR1A HTR2C
3 cardiovascular system MP:0005385 9.97 AVPR1A COMT HTR1A HTR1B MAOA NR3C1
4 endocrine/exocrine gland MP:0005379 9.92 AVPR1A BDNF COMT HTR1B HTR2A NR3C1
5 integument MP:0010771 9.63 BDNF HTR2C NR3C1 PRL SLC6A4 TPH1
6 muscle MP:0005369 9.5 AVPR1A HTR1B HTR2A HTR2C NR3C1 SLC6A4
7 nervous system MP:0003631 9.28 AVPR1A BDNF COMT HTR1A HTR2C MAOA

Drugs & Therapeutics for Borderline Personality Disorder

Drugs for Borderline Personality Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 126)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Citalopram Approved Phase 4,Phase 2,Not Applicable 59729-33-8 2771
2
Dopamine Approved Phase 4,Phase 2,Not Applicable 62-31-7, 51-61-6 681
3
Risperidone Approved, Investigational Phase 4,Not Applicable 106266-06-2 5073
4
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
5
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
6
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
7 Omega 3 Fatty Acid Phase 4
8 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
9 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
10 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Not Applicable
11 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Not Applicable
12 Antidepressive Agents Phase 4,Phase 3,Phase 2,Not Applicable
13 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
14 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
15 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
16 Serotonin Agents Phase 4,Phase 3,Phase 2,Not Applicable
17 Antidepressive Agents, Second-Generation Phase 4,Phase 2,Not Applicable
18 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
19 Parasympatholytics Phase 4,Phase 2,Not Applicable
20 Muscarinic Antagonists Phase 4,Phase 2,Not Applicable
21 Antiparkinson Agents Phase 4,Phase 2,Not Applicable
22 Cholinergic Antagonists Phase 4,Phase 2,Not Applicable
23 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
24 Cholinergic Agents Phase 4,Phase 2,Not Applicable
25 Dopamine Antagonists Phase 4,Phase 2,Not Applicable
26 Serotonin Antagonists Phase 4,Phase 2,Not Applicable
27 Dopamine Agents Phase 4,Phase 2,Not Applicable
28 Anticonvulsants Phase 4,Phase 3,Not Applicable
29 Calcium, Dietary Phase 4
30 Sodium Channel Blockers Phase 4
31 Diuretics, Potassium Sparing Phase 4
32 calcium channel blockers Phase 4
33 Hormones Phase 4,Phase 2,Not Applicable
34 Cytochrome P-450 Enzyme Inhibitors Phase 4
35 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
36
Serotonin Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 50-67-9 5202
37
Ethanol Approved Phase 3,Phase 2,Not Applicable 64-17-5 702
38
Naltrexone Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 16590-41-3 5360515
39
Selegiline Approved, Investigational, Vet_approved Phase 3 14611-51-9 5195 26757
40
Olanzapine Approved, Investigational Phase 3,Not Applicable 132539-06-1 4585
41 Narcotic Antagonists Phase 3,Phase 2,Not Applicable
42 Narcotics Phase 3,Phase 2,Not Applicable
43 Quetiapine Fumarate Phase 3,Phase 2 111974-72-2
44 Antiemetics Phase 3,Not Applicable
45 Gastrointestinal Agents Phase 3,Not Applicable
46 Analgesics, Opioid Phase 3,Not Applicable
47 Anti-Infective Agents, Local Phase 3,Phase 2
48 Anti-Infective Agents Phase 3,Phase 2,Phase 1
49
Acetaminophen Approved Phase 2 103-90-2 1983
50
Ziprasidone Approved Phase 2 146939-27-7 60854

Interventional clinical trials:

(show top 50) (show all 166)
# Name Status NCT ID Phase Drugs
1 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder Unknown status NCT00437099 Phase 4 Omacor®;Placebo
2 Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder Completed NCT00634062 Phase 4 Lamotrigine;Placebo
3 Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder Completed NCT00533117 Phase 4 Fluoxetine
4 Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality Disorder Completed NCT00834834 Phase 4 Fluoxetine;Citalopram
5 Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder Completed NCT00204347 Phase 4 risperidone
6 Effects of Comorbid Personality Disorder on the Treatment of Bipolar I Disorder Completed NCT00178061 Phase 4
7 BOSCOT : A Randomised Controlled Trial of Cognitive Behavioural Therapy in Borderline Personality Disorder Completed NCT00538135 Phase 3
8 Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD) Completed NCT00880919 Phase 3 quetiapine extended-release;Placebo
9 Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder Completed NCT01912391 Phase 3 Selegiline;Placebo (for Selegiline)
10 Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder Completed NCT00122070 Phase 3 Quetiapine Fumarate
11 Olanzapine in Patients With Borderline Personality Disorder Completed NCT00091650 Phase 3 Olanzapine;placebo
12 Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder Completed NCT00088036 Phase 3 Olanzapine
13 The Short-Term MBT Project Recruiting NCT03677037 Phase 3
14 Naltrexone in Borderline Personality Disorder Terminated NCT00124839 Phase 3 Naltrexone
15 Topiramate for Treatment of Patients With Borderline Personality Disorder and Alcohol Dependence Withdrawn NCT00463775 Phase 3 Topiramate
16 Acetaminophen and Social Processes Unknown status NCT02108990 Phase 2 Acetaminophen
17 Central Meditation and Imagery Therapy for Augmentation of Borderline Personality Disorder Treatment Completed NCT02125942 Phase 1, Phase 2
18 Ziprasidone in the Treatment of Borderline Personality Disorder Completed NCT00635921 Phase 2 ziprasidone;Placebo
19 Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder Completed NCT01103180 Phase 2 Escitalopram
20 Verkes Borderline Study: The Effect of Quetiapine on Borderline Personality Disordered Patients Completed NCT00254748 Phase 2 Quetiapine fumarate;Placebo
21 Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder Completed NCT01133301 Phase 2 Naltrexone;Placebo
22 Psychodynamic Therapy For Co-occurring Borderline Personality Disorder and Alcohol Use Disorder Completed NCT00145678 Phase 2
23 Treating PTSD in Patients With Borderline Personality Disorder Completed NCT01081314 Phase 1, Phase 2
24 Treatment of Suicidal Women With Borderline Personality Disorder Completed NCT00183651 Phase 2
25 Oxytocin as Adjunctive Therapy for Schizophrenia Completed NCT01699997 Phase 2 Oxytocin;Placebo
26 Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms Completed NCT01189812 Phase 2 Lithium Carbonate;Placebo;Citalopram
27 Cognitive Therapy for PTSD in Addiction Treatment Completed NCT00685451 Phase 1, Phase 2
28 Brexpiprazole in Borderline Personality Disorder Recruiting NCT03418675 Phase 2 Rexulti;Placebo
29 A Novel Drug for Borderline Personality Disorder Recruiting NCT02097706 Phase 2 NMDA receptor antagonist (active drug)
30 Botulinum Toxin A for Emotional Stabilization in Borderline Personality Disorder (BPD) Recruiting NCT02728778 Phase 2 incobotulinumtoxin A
31 Ketamine in Borderline Personality Disorder Recruiting NCT03395314 Phase 2 Ketamine;Midazolam
32 Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood Disorders Recruiting NCT02824627 Phase 2 Oxytocin;Placebo
33 Emotional Regulation and Impulsivity Among Adolescents With Borderline Personality Disorder Not yet recruiting NCT03209102 Phase 2
34 Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD) Terminated NCT01212588 Phase 2 mifepristone;Placebo
35 N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD Terminated NCT00539188 Phase 2 N-Acetylcysteine;placebo
36 Creativity Group for Borderline Personality Disorder Unknown status NCT01343550 Phase 1
37 Outcome of Crisis Intervention for Subjects With Borderline Personality Disorder or Post-Traumatic Stress Disorder Unknown status NCT00269139 Phase 1
38 20 Weeks DBT Group Skills Training Study Completed NCT01193205 Phase 1
39 Early Study of N-Acetylcysteine to Treat Deliberate Self-Harm in Adolescents Completed NCT01111734 Phase 1 fMRI
40 Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations Recruiting NCT02149823 Phase 1 Syntocinon 24 Intranasal Units (IU);Syntocinon 40 Intranasal Units (IU);Intranasal Placebo
41 Trial of Effect of High-frequency Transcranial Magnetic Stimulation in the Management of Borderline Personality Disorder Unknown status NCT01602497 Not Applicable
42 Event Related Potentials in Borderline Personality Disorder and Major Depression Unknown status NCT01469663
43 Emotional Reaction and Self Injury in Patients With Borderline Personality Disorder and Healthy Controls Unknown status NCT03149926
44 Promoting Recovery Processes in Women With Borderline Personality Disorder Using a Dynamic Cognitive Intervention Unknown status NCT01531634 Not Applicable
45 Guanfacine to Treat Borderline Personality Disorder Unknown status NCT00358969 Not Applicable guanfacine (Tenex)
46 A Randomized Control Trial of Narrative Exposure Therapy Versus Treatment as Usual in the Therapy of Borderline Personality Disorder Unknown status NCT01033708 Not Applicable
47 Cognitive Therapy Versus Supportive Therapy in Borderline Personality Disorder Unknown status NCT00131781 Not Applicable
48 Connectivity and Social Cognition in Adolescent Girls With Borderline Personality Disorder, a Pilot Study Unknown status NCT03139825 Not Applicable
49 A Double Blind Crossover Study on the Effect of MPH on Decision-making Ability of Adults With BPD Compared to Adults With ADHD and Healthy Adults Unknown status NCT01426984 Not Applicable methylphenidate
50 DBT in Borderline Personality Disorder Unknown status NCT00252031 Not Applicable

Search NIH Clinical Center for Borderline Personality Disorder

Cochrane evidence based reviews: borderline personality disorder

Genetic Tests for Borderline Personality Disorder

Anatomical Context for Borderline Personality Disorder

MalaCards organs/tissues related to Borderline Personality Disorder:

42
Brain, Cortex, Amygdala, Pituitary, Testes, Prefrontal Cortex, Eye

Publications for Borderline Personality Disorder

Articles related to Borderline Personality Disorder:

(show top 50) (show all 3048)
# Title Authors Year
1
Violent Offending in Borderline Personality Disorder and Attention Deficit/ Hyperactivity Disorder. ( 30844407 )
2019
2
Group psychotherapy for borderline personality disorder: A meta-analysis of randomized-controlled trials. ( 30869973 )
2019
3
Recent developments in psychosocial interventions for borderline personality disorder. ( 31069059 )
2019
4
Changes in facial emotion expression during a psychotherapeutic intervention for patients with borderline personality disorder. ( 31071663 )
2019
5
Staff and client perspectives of the Open Borders programme for people with borderline personality disorder. ( 31081282 )
2019
6
Inpatient Treatment for Patients With Borderline Personality Disorder. ( 31083028 )
2019
7
Effectiveness of a 5-Week Inpatient Dialectical Behavior Therapy for Borderline Personality Disorder. ( 31083031 )
2019
8
QTc dispersion and interval changes in drug-free borderline personality disorder adolescents. ( 31089814 )
2019
9
Mental health services, care provision, and professional support for people diagnosed with borderline personality disorder: systematic review of service-user, family, and carer perspectives. ( 31099717 )
2019
10
A comprehensive evaluation of emotional responsiveness in borderline personality disorder: a support for hypersensitivity hypothesis. ( 31110772 )
2019
11
Hypothalamic-pituitary-adrenal axis functioning in borderline personality disorder: A meta-analysis. ( 30500331 )
2019
12
Emotional impulsivity is connected to suicide attempts and health care utilization in patients with borderline personality disorder. ( 30503219 )
2019
13
Differential Change of Borderline Personality Disorder Traits During Dialectical Behavior Therapy for Adolescents. ( 30036173 )
2019
14
Perceived Invalidation in Adolescent Borderline Personality Disorder: An Investigation of Parallel Reports of Caregiver Responses to Negative Emotions. ( 30069665 )
2019
15
A randomized controlled trial of a mentalization-based intervention (MBT-FACTS) for families of people with borderline personality disorder. ( 29999394 )
2019
16
Bipolar affective disorder and borderline personality disorder: Differentiation based on the history of early life stress and psychoneuroendocrine measures. ( 29702176 )
2019
17
Mentalization-based treatment or psychodynamic treatment programmes for patients with borderline personality disorder - the impact of clinical severity. ( 29582581 )
2019
18
Relations of mindfulness facets with psychological symptoms among individuals with a diagnosis of obsessive-compulsive disorder, major depressive disorder, or borderline personality disorder. ( 29575447 )
2019
19
The Effectiveness of Dialectical Behavior Therapy Skills Training Group vs. Cognitive Therapy Group on Reducing Depression and Suicide Attempts for Borderline Personality Disorder in Taiwan. ( 29528807 )
2019
20
Borderline Personality Disorder: Associations Between Dimensional Personality Profiles and Self-Destructive Behaviors. ( 29505390 )
2019
21
A Randomized Controlled Trial of Group Psychoeducation for Carers of Persons With Borderline Personality Disorder. ( 29505385 )
2019
22
Mentalization in Adolescents With Borderline Personality Disorder: A Comparison With Healthy Controls. ( 29469664 )
2019
23
Reviewing the clinical significance of 'fear of abandonment' in borderline personality disorder. ( 30403145 )
2019
24
Gender differences and similarities in aggression, suicidal behaviour, and psychiatric comorbidity in borderline personality disorder. ( 30353921 )
2019
25
Borderline personality disorder traits and suicide risk: The mediating role of insomnia and nightmares. ( 30326346 )
2019
26
Screening for depression with the Edinburgh Postnatal Depression Scale and finding borderline personality disorder. ( 30309241 )
2019
27
An exploration of self-compassion and self-criticism in the context of personal recovery from borderline personality disorder. ( 30226078 )
2019
28
Psychotic symptoms in borderline personality disorder: an update. ( 30169467 )
2019
29
Effectiveness of Electroconvulsive Therapy in Patients With Major Depressive Disorder and Comorbid Borderline Personality Disorder. ( 30113988 )
2019
30
The Clinical Significance of Subthreshold Borderline Personality Disorder Features in Outpatient Youth. ( 30036169 )
2019
31
Momentary assessment of everyday physical pain in outpatients with borderline personality disorder. ( 30024195 )
2019
32
Low positive affect display mediates the association between borderline personality disorder and negative evaluations at zero acquaintance. ( 30867910 )
2019
33
Stuck in a negative me: fMRI study on the role of disturbed self-views in social feedback processing in borderline personality disorder. ( 30867073 )
2019
34
Stigma perpetuation at the interface of mental health care: a review to compare patient and clinician perspectives of stigma and borderline personality disorder. ( 30862201 )
2019
35
Getting Specific about Emotion and Self-Inflicted Injury: An Examination Across Emotion Processes in Borderline Personality Disorder. ( 30856367 )
2019
36
What Do Individuals With Borderline Personality Disorder Want From Treatment? A Study of Self-generated Treatment and Recovery Goals. ( 30849065 )
2019
37
Aberrant functional connectivity profiles of brain regions associated with salience and reward processing in female patients with borderline personality disorder. ( 30847803 )
2019
38
Mirror neuron activations in encoding of psychic pain in borderline personality disorder. ( 30844640 )
2019
39
Dependency, mood instability, and inconsequence traits for discriminating borderline personality disorder. ( 30843964 )
2019
40
Borderline Personality Disorder: Clinical Guidelines for Treatment. ( 30840560 )
2019
41
Mixed methods evaluation of an educational intervention to change mental health nurses' attitudes to people diagnosed with borderline personality disorder. ( 30830704 )
2019
42
Multimodal assessment of emotional reactivity and regulation in response to social rejection among self-harming adults with and without borderline personality disorder. ( 30816776 )
2019
43
Pharmacologic Treatment of Borderline Personality Disorder. ( 30811158 )
2019
44
Personal and parents' life stories in patients with borderline personality disorder. ( 30809831 )
2019
45
EEG-vigilance regulation in borderline personality disorder. ( 30796933 )
2019
46
Day hospital versus intensive out-patient mentalisation-based treatment for borderline personality disorder: multicentre randomised clinical trial. ( 30791963 )
2019
47
Psychophysiological stress response and memory in borderline personality disorder. ( 30788063 )
2019
48
Are Impairments in Theory of Mind Specific to Borderline Personality Disorder? ( 30785865 )
2019
49
Change of Emotional Experience in Major Depression and Borderline Personality Disorder During Psychotherapy: Associations With Depression Severity and Personality Functioning. ( 30785864 )
2019
50
Attitudes of Mental Health Staff Toward Patients With Borderline Personality Disorder: An Italian Cross-Sectional Multisite Study. ( 30785861 )
2019

Variations for Borderline Personality Disorder

Expression for Borderline Personality Disorder

Search GEO for disease gene expression data for Borderline Personality Disorder.

Pathways for Borderline Personality Disorder

Pathways related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.26 AVPR1A HTR1A HTR1B HTR2A HTR2C NR3C1
2 12.03 BDNF HTR1A HTR1B
3
Show member pathways
11.97 AVPR1A HTR2A HTR2C
4 11.91 BDNF HTR1A HTR2A MAOA NR3C1 SLC6A4
5
Show member pathways
11.66 HTR1A HTR1B HTR2A HTR2C
6 11.56 HTR1A HTR1B HTR2A HTR2C MAOA SLC6A4
7 11.49 FKBP5 NR3C1 PRL
8
Show member pathways
10.98 COMT MAOA SLC6A4
9 10.8 HTR2A HTR2C
10
Show member pathways
10.78 COMT MAOA TPH1
11
Show member pathways
10.62 COMT MAOA
12 10.61 HTR1A HTR1B HTR2A HTR2C MAOA SLC6A4
13 10.6 COMT MAOA

GO Terms for Borderline Personality Disorder

Cellular components related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.73 AVPR1A HTR1A HTR1B HTR2A HTR2C SLC6A4
2 integral component of presynaptic membrane GO:0099056 9.33 HTR1B HTR2A SLC6A4
3 dendrite GO:0030425 9.1 BDNF COMT HTR1A HTR1B HTR2A HTR2C
4 serotonergic synapse GO:0099154 8.96 HTR1B SLC6A4

Biological processes related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.93 AVPR1A HTR1A HTR2A PRL
2 chemical synaptic transmission GO:0007268 9.83 HTR1A HTR1B HTR2A HTR2C
3 memory GO:0007613 9.72 BDNF HTR2A SLC6A4
4 positive regulation of fat cell differentiation GO:0045600 9.67 HTR2A HTR2C TPH1
5 feeding behavior GO:0007631 9.62 HTR1B HTR2C
6 regulation of dopamine secretion GO:0014059 9.62 HTR1B HTR2A
7 behavioral fear response GO:0001662 9.61 HTR1A HTR2C
8 positive regulation of vasoconstriction GO:0045907 9.61 AVPR1A HTR2A
9 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.61 HTR1A HTR1B HTR2A
10 bone remodeling GO:0046849 9.6 HTR1B TPH1
11 circadian rhythm GO:0007623 9.59 SLC6A4 TPH1
12 catecholamine metabolic process GO:0006584 9.58 COMT MAOA
13 neurotransmitter catabolic process GO:0042135 9.58 COMT MAOA
14 regulation of behavior GO:0050795 9.57 HTR1A HTR1B
15 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.56 HTR1B HTR2A
16 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.56 HTR1A HTR1B HTR2A HTR2C
17 dopamine catabolic process GO:0042420 9.54 COMT MAOA
18 activation of phospholipase C activity GO:0007202 9.54 AVPR1A BDNF HTR2A
19 sperm ejaculation GO:0042713 9.51 AVPR1A SLC6A4
20 vasoconstriction GO:0042310 9.5 HTR1A HTR1B SLC6A4
21 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.48 HTR2A HTR2C
22 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.46 HTR1A HTR1B
23 phospholipase C-activating serotonin receptor signaling pathway GO:0007208 9.4 HTR2A HTR2C
24 response to drug GO:0042493 9.35 COMT HTR1B HTR2A HTR2C SLC6A4
25 serotonin receptor signaling pathway GO:0007210 9.33 HTR1A HTR2A HTR2C
26 behavior GO:0007610 8.92 HTR1A HTR1B HTR2A HTR2C
27 signal transduction GO:0007165 10.11 AVPR1A HTR1A HTR1B HTR2A HTR2C NR3C1
28 G protein-coupled receptor signaling pathway GO:0007186 10.04 AVPR1A HTR1A HTR1B HTR2A HTR2C

Molecular functions related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.77 AVPR1A HTR1A HTR1B HTR2A HTR2C
2 drug binding GO:0008144 9.5 HTR1B HTR2A HTR2C
3 neurotransmitter receptor activity GO:0030594 9.46 HTR1A HTR1B HTR2A HTR2C
4 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.26 HTR2A HTR2C
5 G protein-coupled serotonin receptor activity GO:0004993 9.26 HTR1A HTR1B HTR2A HTR2C
6 serotonin binding GO:0051378 9.02 HTR1A HTR1B HTR2A HTR2C SLC6A4

Sources for Borderline Personality Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....